MedPath

Ezetimibe (+) Simvastatin vs. Atorvastatin Comparative Study in DM or Metabolic Syndrome Patients (0653A-093)

Phase 4
Completed
Conditions
Hypercholesterolemia
Interventions
Registration Number
NCT00157924
Lead Sponsor
Organon and Co
Brief Summary

An efficacy and safety study of ezetimibe (+) simvastatin compared to atorvastatin at week 6 in diabetics or metabolic syndrome patients in Korea.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
190
Inclusion Criteria
  • Clinical diagnosis of hypercholesterolemia
  • Drug naive or statin treated but inadequately controlled patients against NCEP ATP III guideline goal
Exclusion Criteria
  • Hypersensitivity to HMG-CoA inhibitor or Ezetimibe

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1simvastatin (+) ezetimibe1. simvastatin/ezetimibe 10/20mg
2atorvastatin2. atorvastatin 10mg
Primary Outcome Measures
NameTimeMethod
LDL-C lowering efficacy6 weeks
Secondary Outcome Measures
NameTimeMethod
Safety6 weeks
© Copyright 2025. All Rights Reserved by MedPath